Iovance shares climb after hours ahead of lung-cancer data presentation

what happened

According to Stocktwits, shares of Iovance Biotherapeutics (IOVA) gained roughly 12% in extended trading on Wednesday. Investors are anticipating lung-cancer results that the company has promised to present on Thursday, hoping its cell therapy can perform beyond melanoma. During the regular session the stock had already edged up almost 2%, bringing its weekly advance to 5%.

The company will discuss lifileucel, a one-time tumor-infiltrating lymphocyte therapy, in patients with nonsquamous metastatic non-small cell lung cancer who have already received treatment. Earlier, Iovance reported initial findings in two soft tissue cancers: in a small pilot, four of eight evaluable patients reached a partial response, a 50% rate, and every response was still ongoing at the September 9 cutoff. Lifileucel is already marketed as Amtagvi for previously treated advanced melanoma.

The firm also published final Phase 2 data on lifileucel combined with pembrolizumab as a first-line treatment for advanced melanoma. Among 24 patients, 62.5% had a confirmed response, and 29.2% achieved a complete response.

why it matters

Stocktwits notes that Iovance stock is up 442% year to date, so even a single clinical update can move the shares sharply in either direction. Traders will watch whether the new lung-cancer data broadens the potential market for the therapy, while disappointing results often erase short-term gains quickly.

tags

instruments